Page 115 - Read Online

Mathew et al. Vessel Plus 2020;4:11 I http://dx.doi.org/10.20517/2574-1209.2019.35 Page 11 of 15

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, et al. Updated clinical classification of pulmonary hypertension. J Am
Coll Cardiol 2013;62:D34-41.
2. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, et al. Haemodynamic definitions and updated clinical classification
of pulmonary hypertension. Eur Respir J 2019;53:1801913.
3. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic
review. Eur Respir J 2009;34:888-94.
4. D’Alonzo GE, Barst RJ, Ayers SM, Bergofsky EH, Brundage BH, et al. Survival in patients with primary pulmonary hypertension.
Results from a national prospective registry. Ann Intern Med 1991;115:343-9.
5. Humbert M, Sitbbon O, Chaouat A, Bertocchi M, Habib G, et al. Survival in patients with idiopathic, familial, and anorexigen-associated
pulmonary arterial hypertension in modern management era. Circulation 2010;122:156-63.
6. Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir
J 2007;30:1103-10.
7. Pogoriler JE, Rich S, Archer SL, Husain AN. Persistence of complex vascular lesions despite prolonged prostacyclin therapy of
pulmonary arterial hypertension. Histopathology 2012;61:597-609.
8. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, et al. Cellular and molecular pathobiology of pulmonary arterial
hypertension. J Am Coll Cardiol 2004;43:13S-24.
9. Mathew R. Inflammation and pulmonary hypertension. Cardiol Rev 2010;18:67-72.
10. Humbert M, Monti G, Brenot F, Sitbon O, Portier A, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe
primary pulmonary hypertension. Am J Respir Crit Care Med 1995;151:1628-31.
11. Bhargava A, Kumar A, Yuan N, Gewitz MH, Mathew R. Monocrotaline induces interleukin-6 mRNA expression in rat lungs. Heart Dis
1999;1:126-32.
12. Balabanian K, Foussat A, Dorfmüller P, Durand-Gasselin I, Capel F, et al. CX (3) C chemokine fractalkine in pulmonary arterial
hypertension. Am J Respir Crit Care Med 2002;165:1419-25.
13. Dorfmüller P, Zarka V, Durand-Gasselin I, Monti G, Balabanian K, et al. Chemokine RANTES in severe pulmonary arterial hypertension.
Am J Respir Crit Care Med 2002;165:534-9.
14. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform
lesions of pulmonary hypertension. Am J Pathol 1994;144:275-85.
15. Stacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, et al. Modern age pathology of pulmonary arterial hypertension. Am J
Respir Crit Care Med 2012;186:261-72.
16. Huang J, Wolk JH, Gewitz MH, Mathew R. Caveolin-1 expression during the progression of pulmonary hypertension. Exp Biol Med
2012;237:856-65.
17. Huang J, Frid M, Gewitz MH, Fallon JT, Stenmark K, et al. Hypoxia-induced pulmonary hypertension and chronic lung disease:
caveolin-1 dysfunction an important underlying feature. Pulm Circulation 2019;9:2045894019837876.
18. Stenmark KR, Frid MG, Graham BB, Tuder RM. Dynamic and diverse changes in the functional properties of vascular smooth muscle
cells in pulmonary hypertension. Cardiovasc Res 2018;114:551-64.
19. Harrell CR, Markovic BS, Fellabaum C, Arsenijevic A, Djonov V, et al. Molecular mechanisms underlying therapeutic potential of
pericytes. J Biomed Sci 2018;25:21.
20. Ricard N, Tu L, Le Hiress M, Huertas A, Phan C, et al. Increased pericyte coverage mediated by endothelial-derived fibroblast growth
factor-2 and interleukin-6 is a source of smooth muscle–like cells in pulmonary hypertension. Circulation 2014;129:1586-97.
21. Bordenave J, Tu L, Berrebeh N, Thuillet R, Cumont A, et al. Lineage tracing reveals the dynamic contribution of pericytes to the blood
vessel remodeling in pulmonary hypertension. Arterioscler Thromb Vasc Biol 2020;40:766-82.
22. 22. Yuan K, Shao NY, Hennigs JK, Discipulo M, Orcholski ME, et al. Increased pyruvate dehydrogenase kinase 4 expression in lung
pericytes is associated with reduced endothelial-pericyte interactions and small vessel loss in pulmonary arterial hypertension. Am J
Pathol 2016;186:2500-14.
23. Huang J, Wolk JHG, Gewitz MH, Loyd JE, West J, et al. Enhnaced caveolin-1 expression in smooth muscle cells: possible prelude to
neointima formation. World J Cardiol 2015;7:671-54.
24. Mathew R, Huang J, Katta UD, Krishnan U, Sandoval C, et al. Immunosuppressant-induced endothelial damage and pulmonary
hypertension. J Pediatr Hematol Oncol 2011;33:55-8.
25. Huang J, Mathew R. Loss of cavin1 and expression of p-Caveolin-1 in pulmonary hypertension: possible Role in Neointima Formation.
World J Hypertension 2019;9:17-29.
26. Sakao S, Taraseviciene-Stewart L, Lee D, Wood K, Cool D, et al. Vascular endothelial growth factor receptor blockade by SU5416